Published in Clin Exp Immunol on November 01, 1991
Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest (1998) 1.80
Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci U S A (1992) 1.13
Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One (2011) 1.07
Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology (1993) 1.01
Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol (1993) 1.01
Anti-idiotypic activity against anti-myeloperoxidase antibodies in pooled human immunoglobulin. Clin Exp Immunol (1994) 0.82
Normal IgG downregulates the intracellular superoxide level and attenuates migration and permeability in human aortic endothelial cells isolated from a hypertensive patient. Hypertension (2012) 0.81
In vitro effects of polyvalent immunoglobulin for intravenous use. J Neurol Neurosurg Psychiatry (1994) 0.81
Treatment of vasculitis. Br J Clin Pharmacol (1993) 0.80
Passage of intravenous immunoglobulin and interaction with the CNS. J Neurol Neurosurg Psychiatry (1994) 0.79
Adverse effects of treatment with intravenous immunoglobulins for neurological diseases. J Neurol (2006) 0.78
Immunoglobulin treatment reduces atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice via the complement system. Clin Exp Immunol (2005) 0.78
The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. J Clin Immunol (1997) 0.78
Role of Natural Autoantibodies and Natural IgM Anti-Leucocyte Autoantibodies in Health and Disease. Front Immunol (2016) 0.77
Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg. Clin Exp Immunol (2014) 0.77
Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin). Immunology (1998) 0.77
Variability of the inhibition by total immunoglobulin of in vitro autoantibody-mediated erythrophagocytosis by mouse macrophages. Clin Exp Immunol (2006) 0.75
Common idiotypes expressed on human, monoclonal, abnormal immunoglobulins and cryoglobulins with polyreactive autoantibody activities. Clin Exp Immunol (1993) 0.75
A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med (1991) 5.76
The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med (1986) 4.49
High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet (1981) 4.39
Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today (1991) 3.35
High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology (1990) 3.05
Second generation immune networks. Immunol Today (1991) 2.97
Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med (1982) 2.83
Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet (1984) 2.47
Clinical uses of intravenous immunoglobulins. Ann Intern Med (1990) 2.29
Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet (1984) 2.08
Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med (1986) 2.01
Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet (1985) 1.88
Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet (1991) 1.76
High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology (1990) 1.69
Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum (1990) 1.57
The T-cell receptor repertoire and autoimmune diseases. Annu Rev Immunol (1989) 1.54
Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci U S A (1987) 1.49
Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol (1989) 1.46
Expression of three cross-reactive idiotypes on rheumatoid factor autoantibodies from patients with autoimmune diseases and seropositive adults. J Immunol (1986) 1.37
Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol (1984) 1.36
Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev (1989) 1.35
High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet (1983) 1.34
Evidence of unique idiotypic determinants and similar idiotypic determinants on human antithyroglobulin antibodies. Clin Exp Immunol (1983) 1.33
Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood (1983) 1.32
Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet (1983) 1.31
Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest (1989) 1.25
Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest (1990) 1.20
Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol (1991) 1.20
Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders. J Clin Immunol (1990) 1.12
Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. J Rheumatol (1990) 1.08
Idiotypic determinants on human thyroglobulin autoantibodies derived from the serum of Hashimoto patients and EB virus transformed cell lines. Clin Exp Immunol (1984) 1.05
Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol (1988) 1.03
Idiotypic interactions between normal human polyspecific IgG and natural IgM antibodies. Eur J Immunol (1990) 1.02
A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol (1990) 1.01
Intravenous immunoglobulin: a review. Immunodefic Rev (1989) 1.01
Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood (1989) 0.98
Expression of an interspecies idiotype in sera of SLE patients and their first-degree relatives. Clin Exp Immunol (1988) 0.95
Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits. Infect Immun (1987) 0.95
Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet (1988) 0.94
The genetic origin of human autoantibodies. J Immunol (1988) 0.94
On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol (1990) 0.94
Spontaneous reversal of acquired autoimmune dysfibrinogenemia probably due to an antiidiotypic antibody directed to an interspecies cross-reactive idiotype expressed on antifibrinogen antibodies. J Clin Invest (1988) 0.89
Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. N Engl J Med (1987) 0.88
Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Am J Med (1987) 0.88
The role of somatic mutation of immunoglobulin genes in autoimmunity. Annu Rev Immunol (1987) 0.85
Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin. Vox Sang (1986) 0.82
Cooperativity between B lymphocyte membrane molecules: independent ligand occupancy and cross-linking of antigen receptors and Fc gamma receptors down-regulates B lymphocyte function. J Immunol (1986) 0.82
T cell dependence of the "natural" autoreactive B cell activation in the spleen of normal mice. Eur J Immunol (1988) 0.81
Stimulation of B and T cells by in vivo high dose immunoglobulin administration in normal mice. J Autoimmun (1991) 0.81
Suppression of antibody responses to the acetylcholine receptor by natural antibodies. Eur J Immunol (1989) 0.80
Intravenous immunoglobulin therapy. New directions and unanswered questions. Am J Med (1987) 0.77
Evidence for a restricted idiotypic and epitopic specificity of anti-thyroglobulin autoantibodies in patients with autoimmune thyroiditis. Eur J Immunol (1991) 0.77
High dose intravenous gamma globulin for Felty's syndrome. J Rheumatol (1985) 0.77
High dose intravenous gammaglobulin in chronic systemic juvenile arthritis. Br Med J (Clin Res Ed) (1988) 0.77
Clinical results of a prospective, double-blind, placebo-controlled trial of intravenous gamma-globulin in children with chronic chest symptoms. Monogr Allergy (1988) 0.76
Crohn disease and intravenous immunoglobulin G. Ann Intern Med (1990) 0.76
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
Natural autoantibodies. Curr Opin Immunol (1995) 3.00
Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS (1998) 2.90
Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet (1984) 2.47
HES 130/0.4 (Voluven) or human albumin in children younger than 2 yr undergoing non-cardiac surgery. A prospective, randomized, open label, multicentre trial. Eur J Anaesthesiol (2008) 2.15
Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS (2000) 1.97
Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol (1985) 1.91
Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis (2000) 1.86
Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. Nephrol Dial Transplant (1994) 1.80
Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis (2001) 1.76
Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS (1998) 1.62
Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med (1979) 1.53
Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol (2000) 1.53
Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci U S A (1987) 1.49
Mapping of the region of complement receptor (CR) 1 required for Plasmodium falciparum rosetting and demonstration of the importance of CR1 in rosetting in field isolates. J Immunol (2000) 1.48
Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol (1989) 1.46
Comparative assessment of five alternative methods for CD4+ T-lymphocyte enumeration for implementation in developing countries. J Acquir Immune Defic Syndr (2001) 1.44
Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med (1991) 1.44
Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol (1998) 1.43
A new type of acquired C1 inhibitor deficiency associated with systemic lupus erythematosus. Arthritis Rheum (2001) 1.43
Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods (1998) 1.41
Binding sites for endotoxins (lipopolysaccharides) on human monocytes. J Immunol (1991) 1.39
Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol (1991) 1.37
Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev (1989) 1.35
Immunohistochemical study of the C5b-9 complex of complement in human kidneys. Kidney Int (1986) 1.33
Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers. Clin Diagn Lab Immunol (2000) 1.26
Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. Proc Natl Acad Sci U S A (1987) 1.23
Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest (1981) 1.23
Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol (1991) 1.20
Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest (1990) 1.20
Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis (2001) 1.20
Invariance and restriction toward a limited set of self-antigens characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of healthy adults. Proc Natl Acad Sci U S A (1995) 1.18
Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1alpha and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis (1997) 1.11
Induction of cell-associated interleukin 1 through stimulation of the adhesion-promoting proteins LFA-1 (CD11a/CD18) and CR3 (CD11b/CD18) of human monocytes. Eur J Immunol (1990) 1.11
Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur J Immunol (1993) 1.11
C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J Immunol (1987) 1.10
Suboptimal C3b/C3bi deposition and defective yeast opsonization. I. Evidence for the absence of essential co-factor activity. Clin Exp Immunol (1985) 1.10
Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol (1998) 1.09
Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. J Infect Dis (2000) 1.08
Active and selective transcytosis of cell-free human immunodeficiency virus through a tight polarized monolayer of human endometrial cells. J Virol (2001) 1.08
The self-reactive antibody repertoire of normal human serum IgM is acquired in early childhood and remains conserved throughout life. Scand J Immunol (1996) 1.08
Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis. Clin Microbiol Infect (2000) 1.08
Induction of IL-1 release through stimulation of the C3b/C4b complement receptor type one (CR1, CD35) on human monocytes. J Immunol (1990) 1.06
Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab (2000) 1.04
Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol (1999) 1.03
Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol (1996) 1.03
Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol (1988) 1.03
Catalytic activity of anti-thyroglobulin antibodies. J Immunol (1995) 1.02
Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy. Lancet (1998) 1.02
Relative inefficiency of terminal complement activation. J Immunol (1988) 1.02
Idiotypic interactions between normal human polyspecific IgG and natural IgM antibodies. Eur J Immunol (1990) 1.02
Natural autoantibodies and complement promote the uptake of a self antigen, human thyroglobulin, by B cells and the proliferation of thyroglobulin-reactive CD4(+) T cells in healthy individuals. Eur J Immunol (2001) 1.01
Analysis of the natural human IgG antibody repertoire: life-long stability of reactivities towards self antigens contrasts with age-dependent diversification of reactivities against bacterial antigens. Eur J Immunol (1995) 1.01
The use of an anesthesia information management system for prediction of antiemetic rescue treatment at the postanesthesia care unit. Anesth Analg (2001) 1.01
Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci U S A (1992) 1.01
Distribution in clusters of complement receptor type one (CR1) on human erythrocytes. J Immunol (1989) 1.01
Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol (1993) 1.01
gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway. Immunology (1988) 1.00
Membrane molecules which trigger the production of interleukin-1 and tumor necrosis factor-alpha by lipopolysaccharide-stimulated human monocytes. Eur J Immunol (1992) 1.00
Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol (1994) 0.99
Human T cells and interleukin 4 inhibit the release of interleukin 1 induced by lipopolysaccharide in serum-free cultures of autologous monocytes. Eur J Immunol (1989) 0.99
Functional role of the alpha-chain of complement receptor type 3 in human eosinophil-dependent antibody-mediated cytotoxicity against schistosomes. J Immunol (1987) 0.98
Population dynamics of natural antibodies in normal and autoimmune individuals. Proc Natl Acad Sci U S A (1991) 0.98
Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor. J Immunol (1986) 0.97
Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie (2005) 0.97
CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin Exp Immunol (1993) 0.97
Detection of Y chromosome DNA as evidence of semen in cervicovaginal secretions of sexually active women. Clin Diagn Lab Immunol (2001) 0.97
Inhibition of complement activation by natural sulfated polysaccharides (fucans) from brown seaweed. Mol Immunol (1994) 0.97
Analysis of natural and disease-associated autoantibody repertoires: anti-endothelial cell IgG autoantibody activity in the serum of healthy individuals and patients with systemic lupus erythematosus. Int Immunol (1994) 0.97
Analysis of the normal human IgG antibody repertoire. Evidence that IgG autoantibodies of healthy adults recognize a limited and conserved set of protein antigens in homologous tissues. J Immunol (1995) 0.97
Kinetics of Borrelia burgdorferi infection in larvae of refractory and competent tick vectors. J Med Entomol (2006) 0.96
Recombinant attenuated bacteria for the delivery of subunit vaccines. Vaccine (2001) 0.96
Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med (1999) 0.96
Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest (1996) 0.96
Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells. J Immunol (1991) 0.96
The complement system in atherosclerosis. Atherosclerosis (1988) 0.96
Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV. Scand J Immunol (1993) 0.96
Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang (1993) 0.96
Immunohistochemical study of complement S protein (Vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b-9 terminal complex. Clin Exp Immunol (1989) 0.95
Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood (1999) 0.95
Intracellular bacteria as targets and carriers for vaccination. Biol Chem (2001) 0.95
Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clin Exp Med (2005) 0.95
Stability of natural self-reactive antibody repertoires during aging. J Clin Immunol (1999) 0.95
Suboptimal C3b/C3bi deposition and defective yeast opsonization. II. Partial purification and preliminary characterization of an opsonic co-factor able to correct sera with the defect. Clin Exp Immunol (1985) 0.95
Autoantibodies to the collagen-like region of C1q are strongly associated with classical pathway-mediated hypocomplementemia in systemic lupus erythematosus. Lupus (1996) 0.95
Borreliacidal activity of saliva of the tick Amblyomma americanum. Med Vet Entomol (2005) 0.95
The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients. Antiviral Res (2000) 0.94
Lysine residues, but not carbohydrates, are required for the regulatory function of H on the amplification C3 convertase of complement. J Immunol (1984) 0.94
Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. J Autoimmun (2001) 0.94